



May 26, 2026

BSE Limited
Floor 25, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Scrip Code: 543271

Trading Symbol: JUBLINGREA

Sub: Press Release and presentation on the financials and operational performance of the Company for the Quarter and Financial Year ended March 31, 2026

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

In continuation of our letter dated April 28, 2026, regarding the Investor and Analyst Meet scheduled to be held later during the day i.e. Tuesday, May 26, 2026, please find enclosed the Press Release and Presentation that will be discussed during the meeting. The above details will also be available on the website of the Company at www.jubilantingrevia.com.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For **Jubilant Ingrevia Limited**

Deepanjali Gulati
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited
1-A, Sector 16-A,
Noida-201 307, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : U24299UP2019PLC122657



Jubilant Ingrevia Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantingrevia.com

PRESS RELEASE

NOIDA, Tuesday, May 26th, 2026

JUBILANT INGREVIA LIMITED – Q4'FY26 RESULTS

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Total Revenue	1,051	1,051	1,179	12%	12%	4,178	4,388	5%
Total EBITDA	155	136	172	26%	11%	557	607	9%
EBITDA Margin (%)	15%	13%	15%			13%	14%	
PAT after Exceptional Items	74	47	86	84%	17%	251	278	11%
PAT Margin (%)	7%	4%	7%			6%	6%	
Basic and Diluted EPS (Rs.)	4.7	3.0	5.5	84%	17%	16	18	11%

1. All figures are in Rs Crore unless otherwise stated

The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended March 31st, 2026.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:

"We are pleased to report a healthy performance in Q4 and FY26. Our Revenue grew 12% YoY and EBITDA increased 11% YoY in Q4 FY26, reflecting our strong execution. A key highlight for the quarter was our effective handling of the Middle East crisis, with no force majeure and zero production loss. The other highlights include successful dispatch from our newly constructed Agro CDMO facility and the acquisition of Remidex to accelerate the growth of our Human Nutrition business.

The Board has recommended a final dividend of ₹2.50 per share (250%), taking total FY26 dividend to ₹5 per share (500%)

Overall chemical Industry's demand remains resilient despite Middle East disruptions. Volumes continue to grow, while pricing has firmed up in last few weeks due to higher crude-linked costs, with effective pass-through to customers. Pharmaceuticals continue to anchor growth with strong volumes and consistent demand. Agrochem saw strong growth, with robust export visibility and successful price increases, especially in second half of the quarter. Nutrition and Personal Care markets witnessed volume and price-led growth, driven by Niacinamide, with strong demand in Feed and Cosmetics.

Future Outlook:

Early outcomes of our Pinnacle journey are clearly visible in our performance, with strong EBITDA growth, an improving portfolio mix, enhanced customer relationships, a robust opportunity pipeline, more efficient cost structure and balance sheet. With improving volume demand and escalated pricing, we are confident of sustained growth going forward across our segments.

For FY27, we expect growth to be led by Specialty Chemicals and Nutrition, along with recovery in Acetyls. We are expecting a sequential growth in revenue and EBITDA in coming quarters, starting with Q1FY27 itself.

We will continue to invest further in the business; the construction of Gajraula Multi Purpose Plant (MPP) is progressing well, this will further strengthen our CDMO growth roadmap."



Commenting on the Company's performance, Mr. Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said:

"Over the past year, we have made strong progress across all strategic pillars, building long-term growth while managing global challenges effectively. Despite Middle East disruptions impacting supply and prices, our diversified sourcing and agility ensured minimal disruption with effective cost pass-through.

Strong customer engagement and timely renegotiations have strengthened resilience, reflected in improved performance in Q4."

Let me share the overall Business update with you all:

- 1) *Q4 recorded highest revenue in 14 quarters at ₹1,179 crore, up 12% YoY, driven by 10% volume growth. EBITDA stood at ₹172 crore, up 11% YoY and 26% QoQ. PAT was ₹86 crore, up 17% YoY and 84% QoQ. Net debt/EBITDA improved to 0.99x. Our net debt has reduced by 11% in 2026*
 - 2) *In Our Speciality Chemical Business, Revenue stood at ₹516 crore rose +6% YoY and 13% QoQ. EBITDA stood at ₹139 crore; with margins at ~27%.*
 - a) *FY26 revenue stood at ₹1,937 crore up +7%, EBITDA stood at ₹510 crore up 21%.*
 - b) *During the quarter, Specialty Chemicals showed strong momentum, driven by volume recovery despite stable pricing, with margins rising above 27%, reflecting robust fundamentals and resilience.*
 - c) *Our Pyridine & derivatives showed strong volume growth.*
 - d) *Our Fine Chemicals & Diketene derivatives recorded steady QoQ and strong YoY growth.*
 - e) *Our CDMO business progressed well with higher realizations and commencement of a large Agro contract, reflecting a shift towards value-added products.*
 - 3) *In our Nutrition & Health Solutions Business Segment, Revenue stood at Rs ₹230 crore up 21% YoY and 15% QoQ. Segments EBITDA stood at ₹32 crore up by 42% QoQ and margins stood at 14%.*
 - a) *FY26 revenue stood at ₹790 crore and EBITDA at ₹100 crore.*
 - b) *We witnessed a strong recovery during the quarter, with growth driven predominantly by volumes across segments.*
 - c) *Growth was led by Niacinamide, supported by Cosmetics demand; Choline also improved with a surge in exports to Europe*
 - d) *We completed the acquisition of Remidex Pharma, expanding presence in human nutrition and premix solutions.*
 - 4) *In our Chemical Intermediate Business Segment, Revenue stood at ₹433 crore, up 15% YoY and 10% QoQ.*
 - a) *Segments EBITDA improvement supported by cost pass-through. In our Chemical Intermediates business, domestic volumes improved on the back of stronger agrochemical and paracetamol demand. We remain optimistic about recovery, supported by European force majeure events and plant closures. While Middle*
-
-



East disruptions firmed input costs, rising acetic acid prices have set the stage for a favorable pricing outlook for the segment going forward.

A quick update on the progress made across 6 pillars of our Pinnacle Vision:

We launched our Pinnacle journey almost two years back. I'm glad to share that we have made significant progress across all pillars of our Pinnacle journey, leading to the creation of a strong foundation for future growth. Let me share a few highlights:

- 1) Across **businesses**, we delivered strong volume growth, Nutrition saw highest B3 volumes in eight quarters and steady Choline growth; Acetyls improved volumes and pricing with market share gains in Europe; Specialty Chemicals continued momentum in Pyridine, Fine Chemicals, and CDMO shipments.*
- 2) Driven by our **customer centric approach**, We now have 100+ opportunities with ₹3,400 crore potential. With 20+ confirmed molecules (~₹1,500 crore) and an additional pipeline of 10+ advanced stage molecules with ₹1100 crore peak revenue.*
- 3) From an **Operations and ESG** perspective, We achieved ₹120+ crore lean savings and glad to share that we achieved 97th percentile in S&P Global CSA ranking. We also successfully commissioned Bharuch CDMO plant in record 14 months reflecting strong execution. WEF Lighthouse Award and successful USFDA audit of our Bharuch site are testament to the world-class infrastructure we are creating at our plants*
- 4) From a **people and organization** perspective, we strengthened leadership with key senior hires in Supply Chain, Manufacturing HR, and Design & Tech, and also transitioned to a verticalized structure to drive focused growth across Nutrition, Pharma, Agro, Cosmetics, Industrial, and Semicon segments. We invested heavily in our R&D and Technical teams in last two years.*
- 5) From an **awards and recognition** perspective, we were certified as a Great Place to Work and ranked among the Top 50 in Manufacturing in India. We were also recognized with the Golden Peacock Award and a British Safety Council distinction.*
- 6) On the **M&A** front, we completed the acquisition of Remidex Pharma to strengthen our Human Nutrition Premixes portfolio.*

The early results from these initiatives have already started to show in our financial results, e.g.

- 33%+ growth in our EBITDA in last two years, despite tough market demand and declining prices; our Q4FY26 run rate EBITDA is 70%+ higher than Q4FY24 EBITDA, signaling the pace of improvement we could showcase in last two years*
- Portfolio mix moving in favor of Specialty Chemicals and Nutrition, contributing 85%+ of overall EBITDA; Specialty Chemicals EBITDA almost doubling in last two years*
- Improved Net Working Capital at 59 days leading to more efficient balance sheet and a Net Debt/EBITDA level of 0.99x*

This strong foundation and the early results give us the confidence that our Pinnacle strategy is working well. FY27 is a pivotal year in this journey where we are hoping to accelerate our growth, starting with Q1FY27 itself."



Q4'FY26 Highlights | Segment Wise Analysis

A. Specialty Chemicals

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Segment Revenue	487	458	516	13%	6%	1,818.0	1,937	7%
% Share of Overall Revenue	46%	44%	44%			44%	44%	
EBITDA	129	116	139	20%	8%	422	510	21%
% EBITDA Margin	27%	25%	27%			23%	26%	
% Contribution to EBITDA ²	76%	76%	72%			67%	75%	

1. All figures are in Rs Crore unless otherwise stated

2. Before adjustment of Unallocated corporate expense/Income

BUSINESS WISE UPDATES

P&P

- Strong **volume momentum in Pyridine & Picolines**
- **Pricing remained muted** with pressure from China continuing; some improvement towards end of quarter

Fine Chemicals

- **Pyridine/ Diketene Derivatives: Volume growth across products** with pricing remained muted
- **Cosmetics: Expanded portfolio beyond Niacinamide**; Products under qualification with customers
- **Industrial: Volume growth across existing customers; New customers added in pipeline**

CDMO

- **Agro: Commenced dispatches of Big CDMO order**
- **Pharma: Grew our pipeline by 3x+ in last 2 years** with innovators and Tier-1 CDMOs
- **Semicon: Building R&D lab at Greater Noida with clean room**; Increase in funnel across key applications

Business Drivers

- Segment revenue improved, driven by **volume recovery across segments**, with Fine and Agro Chemicals leading the overall growth
- EBITDA improved significantly due to **higher share of value-added CDMO products and Improved contribution from Fine Chemicals**

B. Nutrition & Health Solutions

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Segment Revenue	190	201	230	15%	21%	747	790	6%
% Share of Overall Revenue	18%	19%	20%			18%	18%	
EBITDA	29	23	32	42%	9%	102	100	-1%
% EBITDA Margin	16%	11%	14%			14%	13%	
% Contribution to EBITDA ²	17%	15%	17%			16%	15%	

1. All figures are in Rs Crore unless otherwise stated

2. Before adjustment of Unallocated corporate expense/Income

BUSINESS WISE UPDATES

Human Nutrition

- **B3: Steady YoY growth in food and cosmetic volumes**, with some **softness in pricing across food**; cosmetic pricing remained stable
- **CC/CBT: Gaining traction with customers in EU/US**; steady volume scale up in India



- Premixes: Traction with tier-1 customers in India with acquisition of Remidex Pharma

Animal Nutrition

- **B3:** Achieved **highest volumes in the past eight quarters**; Improvement in pricing, driven by strong demand recovery towards second half of quarter
- **Choline:** Increase in volumes with imports easing from China both on a YoY and QoQ basis; **Improving traction in the EU, with rising volumes following anti-dumping duties on China**
- **Premixes:** Volume growth in domestic market; pricing remained stable

Business Drivers

- Revenue growth driven by **strong double-digit volume expansion both QoQ & YoY, led by Niacinamide (Vitamin B3)**, with favorable mix improvement in Choline
- Margins improved QoQ, **supported by a favorable volumes shift in mix toward higher-value end-uses**, with increased contribution from Cosmetics and Food segments

C. Chemical Intermediates Segment

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Segment Revenue	375	393	433	10%	15%	1,612	1,662	3%
% Share of Overall Revenue	36%	37%	37%			39%	38%	
EBITDA	10	15	22	45%	111%	108	73	-32%
% EBITDA Margin	3%	4%	5%			7%	4%	
% Contribution to EBITDA ²	6%	10%	11%			17%	11%	

1. All figures are in Rs Crore unless otherwise stated

2. Before adjustment of Unallocated corporate expense/Income

BUSINESS WISE UPDATES

Acetic Anhydride

- Overall Volume **growth supported by resilient Pharma demand in India and increased market share in Europe; retained market share in India merchant market**
- **Acetic Anhydride volumes grew strongly YoY**, with stable QoQ performance
- **Sharp increase in Acetic Acid prices** due to disruptions in the Middle East

Ethyl Acetate

- **Double-digit growth in Ethyl Acetate** volumes on both QoQ and YoY basis
- **Prices improved**, driven by higher raw material costs, driven by ME disruptions

Business Drivers

- Revenue increased on **both QoQ and YoY basis, driven by overall volume growth and improved realizations**, supported by higher input costs amid Middle East-led crude inflation
- EBITDA growth **driven by higher volumes and better realizations**, supported by **pass-through of increased raw material costs**

3. Income Statement – Q4'FY26

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	QoQ	YoY	FY25	FY26	YoY
Revenue from operations								
a) Sales/Income from operations	1038	1040	1166	12%	12%	4124	4345	5%
b) Other operating income	13	11	13	12%	-4%	54	43	-20%
Total revenue from operations	1051	1051	1179	12%	12%	4178	4388	5%
Other income	8	9	9	4%	11%	38	41	7%
Total income	1060	1060	1188	12%	12%	4215	4429	5%
Expenses								
a) Cost of materials consumed	481	510	597	17%	24%	2050	2105	3%
b) Purchases of stock-in-trade	32	42	44	7%	38%	57	149	162%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	20	4	-23	-671%	-217%	0	41	22739%
d) Employee benefits expense	96	104	106	3%	11%	418	426	2%
e) Finance costs	14	12	12	-5%	-15%	56	49	-12%
f) Depreciation and amortisation expense	39	45	48	7%	23%	158	175	11%
g) Other expenses:								
- Power and fuel expense	104	103	108	5%	4%	464	418	-10%
- Others	171	161	183	13%	7%	670	683	2%
Total expenses	958	981	1076	10%	12%	3872	4046	4%
Profit before share of loss of an associate (3-4)	102	78	112	42%	10%	344	383	11%
Share of loss of an associate		0	0				0	
Exceptional Items		13	0				13	
Profit before tax	102	65	112	71%	10%	344	370	8%
Tax expense								
- Current tax	25	18	27	51%	9%	85	84	-1%
- Deferred tax charge	2	0	-2	-919%	-190%	7	8	6%
Net profit for the period/year	74	47	86	84%	17%	251	278	11%
Earnings per share of ₹ 1 each								
Basic (₹)	4.7	3.0	5.5			15.9	17.6	
Diluted (₹)	4.6	3.0	5.4			15.8	17.5	

All figures are in Rs Crore unless otherwise stated

4. Segment P&L – Q4'FY26

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	QoQ (%)	YoY (%)	FY25	FY26	YoY (%)
Revenue								
Speciality Chemicals	487	458	516	13%	6%	1,818	1,937	7%
Nutrition & Health Solutions	190	201	230	15%	21%	747	790	6%
Chemical Intermediates	375	393	433	10%	15%	1,612	1,662	3%
Total Revenue from Operations	1,051	1,051	1,179	12%	12%	4,178	4,388	5%
Reported EBITDA								
Speciality Chemicals	129	116	139	20%	8%	422	510	21%
Nutrition & Health Solutions	29	23	32	42%	9%	102	100	(1%)
Chemical Intermediates	10	15	22	45%	111%	108	73	(32%)
Unallocated Corporate & One-Off (Expenses)/Income	-14	-30	-21	-	-	-74	-76	2%
PAT	74	47	86	84%	17%	251	278	11%
EPS	4.7	3.0	5.5	84%	17%	16	18	11%
Reported EBITDA Margins								
Speciality Chemicals	27%	25%	27%			23%	26%	
Nutrition & Health Solutions	16%	11%	14%			14%	13%	
Chemical Intermediates	3%	4%	5%			7%	4%	
Net Margin	7%	4%	7%			6.0%	6.3%	

All figures are in Rs Crore unless otherwise stated



5. Debt Position as on 31st March, 2026

Particulars ¹	31-Mar-25	31-Dec-25	31-Mar-26
Long Term Borrowings	453	452	446
Short Term Borrowings	303	268	332
Total Gross Debt	756	720	777
Cash & Equivalent	98	177	190
Total Net Debt	658	543	587
YoY change			-11%

All figures are in Rs Crore unless otherwise stated

- Capex cash outflow for the quarter stood at ₹69 crore, primarily went towards commissioning of CDMO plant at Bharuch and ground breaking of new MMP at Gajraula.
- Compared to Q3'FY26, the Net debt increased marginally due to higher working capital requirements
- The working capital to revenue reduced to 16%, compared to 18% during Q4'FY25.

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to global quality standards and has a broad portfolio of 130+ products.

It has over 45 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50+ plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: www.jubilantingrevia.com.

For more information, please contact:

For Investors

Pavleen Taneja
Jubilant Ingrevia Limited
Ph: +91-120 436 1000
E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Sandipan Ghatak
Ph: +919810776182
E-mail: sandipan.ghatak@jubl.com

Sahir Seth
M: +91 9999270119
E-mail: sahir.seth@adfactorspr.com



Earnings Call details: The company will host earnings call at 5.00 PM IST on 26th May, 2026

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <p> Click here to ExpressJoin the Call</p> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Audio Link:	The Audio link will be available on the company website. Please access the link here - https://jubilantingrevia.com/investors/financials/quarterly-results

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.



INVESTORS PRESENTATION

Q4 & FY 2026



Disclaimer



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

1. The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary
2. Closing Exchange Rate for USD 1 at Rs 94.84 as on March 31, 2026 Rs 89.86 as on December 31, 2025 and Rs 85.5 as on March 31, 2025.

Chairmen's Message on Q4'FY26 Financial Results



*"We are pleased to report a healthy performance in Q4 and FY26. Our **Revenue grew 12% YoY and EBITDA increased 11% YoY**, reflecting our strong execution. A key highlight for the quarter was our effective handling of the Middle East crisis, with no force majeure and zero production loss. The other highlights include **successful dispatch from our newly constructed Agro CDMO facility** and the **acquisition of Remidex** to accelerate the growth of our Human Nutrition business.*

Dividend declaration:

*The Board has recommended a final dividend of ₹2.50 per share (250%), taking total **FY26 dividend to ₹5 per share (500%)***

Markets Update:

*Overall **chemical Industry's** demand remains resilient despite Middle East disruptions. Volumes continue to growth, while pricing has firmed up in last few weeks due to higher crude-linked costs, with effective pass-through to customers.*

***Pharmaceuticals** continue to anchor growth with strong volumes and consistent demand.*

***Agrochem** saw strong growth, with robust export visibility and successful price increases, esp. in second half of the quarter.*

***Nutrition and Personal Care markets** witnessed volume and price-led growth, driven by Niacinamide, with strong demand in Feed and Cosmetics.*

Future Outlook:

*Early outcomes of our **Pinnacle journey** are clearly visible in our performance, with strong EBITDA growth, an improving portfolio mix, enhanced customer relationships, a robust opportunity pipeline, more efficient cost structure and balance sheet. With improving volume demand and escalated pricing, we are confident of sustained growth going forward across our segments.*

For FY27, we expect growth to be led by Specialty Chemicals and Nutrition, along with recovery in Acetyls. We are expecting a sequential growth in revenue and EBITDA in coming quarters, starting with Q1FY27 itself.

We will continue to invest further in the business; the construction of Gajraula MPP plant is progressing well, this will further strengthen our CDMO growth roadmap."



Mr. Shyam S Bhartia

Chairman

&

Mr. Hari S Bhartia

Co-Chairman



Table of Contents

06

Pinnacle Journey Update

16

Q4'FY26 Highlights


24

Business Segments Update

Pinnacle Journey Update



Jubilant Ingrevia has a rich legacy spread over the last 45 years and 4 major chapters



Pinnacle Journey: We launched our Pinnacle journey almost 2 yrs back with clear priorities and enablers



PINNACLE GROWTH PILLARS

A Specialty Chemicals

Pyridine & Picoline

Retain Global leadership (#1 position, cost leadership) **Scale up Oilfield chemicals**

Fine Chemicals

P&P derivatives: Maintain leadership position
Diketene derivatives: Expand portfolio; Top 3
Cosmetics: Rapid Scale-up; leverage customer/products

CDMO

Pharma & Agro: Scape up- Europe/US/Japan
Semi-con: Rapid scale-up; new technologies through partnerships

B Nutrition & Health solutions

Animal Nutrition

Feed Vit B3: Extend global leadership position
Feed Vit B4: Consolidate domestic leadership
Pre-mixes: Leadership in India and neighboring markets

Human Nutrition

Cosmetic/Food grade B3: Rapid Scale-up
Choline Salts: Anchor products for food segment
Foray into Premix / other vitamins

C Chemical Intermediates

Acetic Anhydride

Maintain global leadership position in merchant market
 Optimize cost structure

Other Products (Ethyl Acetate, Acetaldehyde, Bio-Acetic Acid, Propionic Anhydride)

Continue to scale in focused markets/ customers
 Optimize cost structure

D

ENABLERS

Customer-first approach
(Key Account Mgmt)

World-class Ops
Best-in-class on **Safety, Quality, ESG**

Deep R&D & Tech focus

Digital transformation

Agile Supply Chain

People / Org

Pinnacle Journey: Created a strong foundation in last 2 years across Pinnacle Growth Pillars and Enablers (1/2)





Customer-first approach



World class Ops



Deep R&D & Tech focus

- **KAM Program:** High engagement with top 40 customers; **100+ opportunities in funnel** (20+ already won)
- **Customer roadshows:** EU, US, Japan, **100+ meetings each year**; increased participation in exhibitions/trade shows
- **Launched new verticals:** Semicon, Human Nutrition and Cosmetics/Personal Care
- **Expansion in focused markets:** US scale up; Japan/SEA focus; Dedicated BD teams in each market

- **USFDA plant** with zero observations
- **WEF Lighthouse award (Bharuch)**
- Dedicated **Technology Cell**
- **Multiple new plants constructed** (2Kcr deployed)
- **Lean savings of 100+ Crs/ year**
- **Top tiers in DJSI** and Ecovadis
- Shift to **green power (35% share)**
- **British Safety awards** for key sites
- **Golden Peacock- Quality award**
- Launch of **5S program for Safety**



- **Senior R&D leadership; Expanded R&D team to 150+**
- **50+ products in pipeline;** highest # products to be launched in FY27
- **Dedicated teams for new growth areas:** Semicon, Cosmetics, Nutrition
- **Investment in new technology:** Flow, Cryogenic, Semicon purification



Pinnacle Journey: Created a strong foundation in last 2 years across Pinnacle Growth Pillars and Enablers (2/2)



Digital

SuperNova program: 50+ Digital/AI initiatives across org, e.g.

- **Launched Gen AI Tool to FastTrack R&D**
- **Smart plants:** Control room, Smart plant; WEF Lighthouse
- **Enabled GenAI across functions:** Legal, Finance, BD
- **Predictive analytics for RM purchasing,** Supplier/ transporter tracking



Agile Supply Chain

- **Rejuvenated, lean team** and processes to bring agility and efficiency
- **Digital interventions:** Predictive analytics on key RMs, inventory mgmt., logistics tracking, MRO mgmt., etc.
- **Strategic partnerships and stable contractual arrangements** with key suppliers

People/ Org

- **Great Place To Work certified** for last two years; amongst top GPTW companies in Manufacturing and Chemicals
- **New and refreshed leadership with new additions across BUs/functions**
- **Verticalised team structure** to bring more focus (high customer centricity)
- **Increased diversity** and dedicated program for Women
- **High performance culture:** Internal talent focus



Pinnacle Journey: Early results of Pinnacle efforts have started to show in our financial results




*Financial numbers in Rs. Cr

BU		FY24	FY26	Growth	Highlights
Specialty	Revenue	1586	1937	+22%	<ul style="list-style-type: none"> Significant growth in topline and bottom-line, despite tough market conditions Pyridine & Picolines: Global share gain, maintained #1 position globally Fine Chem: Growth driven by share gains in pyridine derivatives and scale-up of multiple diketene derivatives. CDMO: Business scale up across agro, pharma and semicon
	EBITDA (%)	248 (~16%)	510 (~27%)	+106%	
Nutrition	Revenue	680	790	+16%	<ul style="list-style-type: none"> B3: Rapid scale up in feed and in cosmetics, enabled with new plant in PC grade B4: Human nutrition launch; Maintained share in B4 in domestic market Premixes: Faster scale up in premixes in animal, launch of human premix (Remidex)
	EBITDA (%)	62 (~9%)	100 (~13%)	+63%	
Chemical Intermediates	Revenue	1870	1662	-11%	<ul style="list-style-type: none"> Tough market, but retained our volume share in domestic with leadership (75%+ share) and gained share in Europe Ethyl Acetate share gain in domestic market
	EBITDA (%)	202 (~11%)	73 (~4%)	-64%	
Unallocated Expenses		(54)	(76)		
Overall	Revenue	4136	4388	6%	
	EBITDA (%)	456 (~11%)	607 (~14%)	33%	

Portfolio Shift: The impact is also visible in our portfolio mix, with Specialty and Nutrition contribution 85%+ of EBITDA



Segment-wise EBITDA Share (%)



Our business has become more 'customer-centric' with a higher focus on offering solutions across 6 focused end-verticals

Our 3 BUs offer solutions....

1 Speciality Chemicals


- Pyridine and Picolines
- **Fine Chemicals:** P&P and Diketene Derivatives, Cosmetics
- **CDMO:** Agro, Pharma and Semicon

2 Nutrition


- **Animal Nutrition:** B3, Choline, Premixes
- **Human Nutrition:** B3, CC/CBT, Premixes

3 Chemical Intermediates

- Acetic Anhydride
- Acetaldehyde
- Ethyl Acetate
- Bio Acetic Acid



...across 6 focused verticals




....fueled by our 35+ chemistries

Balanced mix of revenues across focused verticals; North America and RoW (Japan/SEA) are scaling up fast

Application wise Split


FY26



Pharma and Nutrition are the biggest contributors with ~53% of revenue

Business wise Split


FY26



Specialty Chemicals and Nutrition contribute >62% of revenues

Geography wise Split

FY26



North America & EU drive >32% of revenue


Remidex Acquisition: We added Remidex to our portfolio to accelerate our journey into Human Nutrition premixes business

Acquisition will enable JVL to expand into customized Vitamin and Mineral Premix Solutions

- **WHO-GMP, GAIN, FSSC, ISO & FSSAI certified facility**
- **Strong quality systems and GLP-compliant lab**
- **Trusted manufacturing partner to Tier-1 FMCG companies**



Agro CDMO facility: Completed agro intermediates plant in record time to start supplies to global agro innovator in March



Key highlights

- **Constructed and commissioned within 14 months**
- **Molecule with multi-step chemistry delivered with First-time right approach**
- **1st shipment dispatched to Global Agro innovator in Mar'26**



Q4'FY26 Highlights



Market Overview Q4'FY26: Volume momentum improving across segments; price escalations driven by ME war disruptions



Pharma

- Pharma market is **maintaining its volume growth with most players reporting increase in revenue**
- **Margins pressure in latest quarter** due to **SCM disruption, patent expiries**



Agro

- The agrochemical sector is **witnessing gradual volume recovery** supported by demand normalization
- **Pricing/Margins remain under pressure** due to **competitive intensity (China oversupply)**



Industrial

- Industrial market **remains mixed with marginal improvement in volumes**
- Margins **remained under pressure with slow down** across construction and manufacturing



Personal Care

- The **cosmetics and fragrance sector continues to remain stable in terms of volume growth**, particularly in premium beauty, skincare, and fragrances
- **Profitability remained stable** with new product folios and innovation driving Premiumization and growth



Nutrition

- The nutrition market is **seeing stable-to-improving volumes** driven by demand in health supplements, and functional ingredients
- Profitability **under pressure with fluctuating RM prices** due to SCM disruptions



Semicon

- Semiconductor **market continues volume growth** driven by AI, high performing computing
- **Still in nascent stage; long lead time to scale up**

Several milestones in Q4FY26, building strong pipeline and capabilities for future growth



Business

- **Volume growth across Nutrition:** Highest B3 volume sales in last 8 quarters; Volume growth across Choline
- **Acetyls:** Volume and marginal price uptick; Market Share gain in Europe
- **Specialty:** Continued vol. growth across Pyridine and FC portfolio; CDMO Agro innovator orders shipped out



Customer

- **KAM:** 100+ funnel, 3400Cr+ peak potential
- **8 new molecules won in Q4** (Pharma: 4, Personal Care: 2, Nutrition: 2); **20+ molecules confirmed in last one year**
- **Advanced stage: 10+ molecules, INR ~1100cr** peak revenue



Operations / ESG

- **Lean savings of 120+Cr delivered** in FY26
- 2025 S&P Global Corporate Sustainability Assessment (CSA)- **Achieved 97th percentile**
- **Agile Supply Chain management** during middle-east war disruptions
- **CAPEX approved for Semiconductor R&D and Pilot lab** at Greater Noida



People / Org

- **Senior Talent additions continue:** Senior SCM personnel, New Manufacturing HR Head, Senior Director- Design & Tech,
- **Verticalised org structure** to focus on growth: Nutrition, Pharma, Agro, Cosmetics, Industrial & Semicon



Awards

- **Great place to work certified** for FY27;
- **Top 50 India's best workplaces in Manufacturing and Chemicals**
- **Golden Peacock- National Quality award**
- Distinction in the **British Safety Council International Safety Awards**



M&A

- **Remidex Pharma:** Completed Remidex Pharma acquisition for Human Nutrition Premixes

Financial Results Overview | Q4'FY26 Consolidated




Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Total Revenue	1,051	1,051	1,179	12%	12%	4,178	4,388	5%
Total EBITDA	155	136	172	26%	11%	557	607	9%
EBITDA Margin (%)	15%	13%	15%			13%	14%	
PAT after Exceptional Items	74	47	86	84%	17%	251	278	11%
PAT Margin (%)	7%	4%	7%			6%	6%	
Basic and Diluted EPS (Rs.)	4.7	3.0	5.5	84%	17%	16	18	11%

- Overall growth **driven largely by volume in Q4**, with some **pricing uptick in second half of quarter**
- **Volume growth across all our segments** with nutrition leading the pack.
- **Margin improvement on the back of better mix, scale, price realization** (pass throughs) in second half of quarter and **cost initiatives**
- **Successfully managed the ME war disruptions by securing RM supplies**; no force majeure or supply disruptions to customers

1. All figures are in Rs Crore unless otherwise stated

Note: PAT impacted by Rs 13 Crore due to amendments under the Indian labour code

Achieved Highest Revenue and Profit in last 12 quarters




EBITDA trends: Margin growth achieved across all three businesses

Specialty Chemicals

EBITDA (INR Crs)

Y.o.Y Growth 7%
Q.o.Q Growth 20%




- EBITDA growth driven by volume growth across Fine Chemicals and Pyridine; New CDMO shipments for Agro Innovator
- Growth partially offset by price erosion across businesses (early part of quarter)

Nutrition

EBITDA (INR Crs)

Y.o.Y Growth 9%
Q.o.Q Growth 42%




- B3 Volumes remains the standout growth driver, across the segments, highest in last 2 years
- Margin expansion driven by steady growth in Food and Cosmetics end-use segments

Chemical Intermediates

EBITDA (INR Crs)

Y.o.Y Growth 112%
Q.o.Q Growth 45%



- Immediate pass-through of higher input costs supported revenue growth.
- Improved margins were supported by better realizations in Acetic Anhydride and Ethyl Acetate.

% EBITDA Margins – Before adjustment of Unallocated corporate expense/Income



Business Segments Overview



Specialty Chemicals | Market, Business & Financial Highlights



FINANCIAL HIGHLIGHTS

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Segment Revenue	487	458	516	13%	6%	1,818.0	1,937	7%
% Share of Overall Revenue	46%	44%	44%			44%	44%	
EBITDA	129	116	139	20%	8%	422	510	21%
% EBITDA Margin	27%	25%	27%			23%	26%	
% Contribution to EBITDA ²	76%	76%	72%			67%	75%	

- Segment revenue improved, driven by **volume recovery across segments**, with Fine and Agro Chemicals leading the overall growth
- EBITDA improved significantly due to **higher share of value-added CDMO products and Improved contribution from Fine Chemicals**

BUSINESS WISE UPDATES

P&P

- Strong **volume momentum in Pyridine & Picolines**
- **Pricing remained muted** with pressure from China continuing; some improvement towards end of quarter

Fine Chemicals

- **Pyridine/ Diketene Derivatives: Volume growth across products** with pricing remained muted
- **Cosmetics: Expanded portfolio beyond Niacinamide**; Products under qualification with customers
- **Industrial: Volume growth across existing customers; New customers added in pipeline**

CDMO

- **Agro: Commenced dispatches of Big CDMO order**
- **Pharma: Grew our pipeline by 3x+ in last 2 years** with innovators and Tier-1 CDMOs
- **Semicon: Building R&D lab at Gr. Noida with clean room**; Increase in funnel across key applications

1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income

Nutrition & Health Solutions | Market, Business & Financial Highlights



FINANCIAL HIGHLIGHTS

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Segment Revenue	190	201	230	15%	21%	747	790	6%
% Share of Overall Revenue	18%	19%	20%			18%	18%	
EBITDA	29	23	32	42%	9%	102	100	-1%
% EBITDA Margin	16%	11%	14%			14%	13%	
% Contribution to EBITDA ²	17%	15%	17%			16%	15%	

- Revenue growth driven by **strong double-digit volume expansion both QoQ & YoY, led by Niacinamide (Vitamin B3)**, with favorable mix improvement in Choline
- Margins improved QoQ, **supported by a favorable volumes shift in mix toward higher-value end-uses**, with increased contribution from Cosmetics and Food segments

BUSINESS WISE UPDATES

Human Nutrition

- B3:** Steady **YoY growth in food and cosmetic volumes**, with some **softness in pricing across food**; cosmetic pricing remained stable
- CC/CBT:** Gaining traction with customers in EU/US; steady volume scale up in India
- Premixes:** **Traction with tier-1 customers in India with acquisition of Remidex Pharma**

Animal Nutrition

- B3:** Achieved **highest volumes in the past eight quarters**; Improvement in pricing, driven by strong demand recovery towards second half of quarter
- Choline:** **Increase in volumes with imports easing from China** both on a YoY and QoQ basis; **Improving traction in the EU**, with rising volumes following anti-dumping duties on China
- Premixes:** **Volume growth in domestic market**; pricing remained stable

1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income

Chemical Intermediates | Market, Business & Financial Highlights



FINANCIAL HIGHLIGHTS

Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	Q-o-Q	Y-o-Y	FY25	FY26	Y-o-Y
Segment Revenue	375	393	433	10%	15%	1,612	1,662	3%
% Share of Overall Revenue	36%	37%	37%			39%	38%	
EBITDA	10	15	22	45%	111%	108	73	-32%
% EBITDA Margin	3%	4%	5%			7%	4%	
% Contribution to EBITDA ²	6%	10%	11%			17%	11%	

- Revenue increased on **both QoQ and YoY basis, driven by overall volume growth and improved realizations**, supported by higher input costs amid Middle East-led crude inflation
- EBITDA growth **driven by higher volumes and better realizations**, supported by **pass-through of increased raw material costs**

BUSINESS WISE UPDATES

Acetic Anhydride

- Overall Volume **growth supported by resilient Pharma demand in India and increased market share in Europe; retained market share in India merchant market**
- **Acetic Anhydride volumes grew strongly YoY**, with stable QoQ performance
- **Sharp increase in Acetic Acid prices** due to disruptions in the Middle East

Ethyl Acetate

- **Double-digit growth in Ethyl Acetate volumes on both QoQ and YoY basis**
- **Prices improved**, driven by higher raw material costs, driven by ME disruptions

1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income

Annexures

Annexure I - Income Statement | Consolidated – Q4'FY26



Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	QoQ	YoY	FY25	FY26	YoY
Revenue from operations								
a) Sales/Income from operations	1038	1040	1166	12%	12%	4124	4345	5%
b) Other operating income	13	11	13	12%	-4%	54	43	-20%
Total revenue from operations	1051	1051	1179	12%	12%	4178	4388	5%
Other income	8	9	9	4%	11%	38	41	7%
Total income	1060	1060	1188	12%	12%	4215	4429	5%
Expenses								
a) Cost of materials consumed	481	510	597	17%	24%	2050	2105	3%
b) Purchases of stock-in-trade	32	42	44	7%	38%	57	149	162%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	20	4	-23	-671%	-217%	0	41	22739%
d) Employee benefits expense	96	104	106	3%	11%	418	426	2%
e) Finance costs	14	12	12	-5%	-15%	56	49	-12%
f) Depreciation and amortisation expense	39	45	48	7%	23%	158	175	11%
g) Other expenses:								
- Power and fuel expense	104	103	108	5%	4%	464	418	-10%
- Others	171	161	183	13%	7%	670	683	2%
Total expenses	958	981	1076	10%	12%	3872	4046	4%
Profit before share of loss of an associate (3-4)	102	78	112	42%	10%	344	383	11%
Share of loss of an associate		0	0				0	
Exceptional Items		13	0				13	
Profit before tax	102	65	112	71%	10%	344	370	8%
Tax expense								
- Current tax	25	18	27	51%	9%	85	84	-1%
- Deferred tax charge	2	0	-2	-919%	-190%	7	8	6%
Net profit for the period/year	74	47	86	84%	17%	251	278	11%
Earnings per share of ₹ 1 each								
Basic (₹)	4.7	3.0	5.5			15.9	17.6	
Diluted (₹)	4.6	3.0	5.4			15.8	17.5	

1. All figures are in Rs Crore unless otherwise stated.
Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

Annexure II: Income Statement Segmental – Q4'FY26



Particulars ¹	Q4'FY25	Q3'FY26	Q4'FY26	QoQ (%)	YoY (%)	FY25	FY26	YoY (%)
Revenue								
Speciality Chemicals	487	458	516	13%	6%	1,818	1,937	7%
Nutrition & Health Solutions	190	201	230	15%	21%	747	790	6%
Chemical Intermediates	375	393	433	10%	15%	1,612	1,662	3%
Total Revenue from Operations	1,051	1,051	1,179	12%	12%	4,178	4,388	5%
Reported EBITDA	155	136	172	26%	11%	557	607	9%
Speciality Chemicals	129	116	139	20%	8%	422	510	21%
Nutrition & Health Solutions	29	23	32	42%	9%	102	100	(1%)
Chemical Intermediates	10	15	22	45%	111%	108	73	(32%)
Unallocated Corporate & One-Off (Expenses)/Income	-14	-30	-21	-	-	-74	-76	2%
PAT	74	47	86	84%	17%	251	278	11%
EPS	4.7	3.0	5.5	84%	17%	16	18	11%
Reported EBITDA Margins	15%	13%	15%			13.3%	13.8%	
Speciality Chemicals	27%	25%	27%			23%	26%	
Nutrition & Health Solutions	16%	11%	14%			14%	13%	
Chemical Intermediates	3%	4%	5%			7%	4%	
Net Margin	7%	4%	7%			6.0%	6.3%	

1. All figures are in Rs Crore unless otherwise stated.



Annexure III: Debt Position| As on 31st March 2026

Particulars ¹	31-Mar-25	31-Dec-25	31-Mar-26
Long Term Borrowings	453	452	446
Short Term Borrowings	303	268	332
Total Gross Debt	756	720	777
Cash & Equivalent	98	177	190
Total Net Debt	658	543	587
YoY change			-11%

- Capex cash outflow for the quarter stood at 69 crore, primarily went towards commissioning of CDMO plant at Bharuch and ground breaking of new MMP at Gajraula.
- Compared to Q3'FY26, the Net debt increased marginally due to higher working capital requirements
- The working capital to revenue reduced to 16%, compared to 18% during Q4'FY25.

Annexure III - Conference Call Details

Date : May 26th, 2026
Time : 05:00 pm IST

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p>   <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	<p>+ 91 22 6280 1141 + 91 22 7115 8042</p>
Toll Free Number:	<p>USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448</p>
Audio Link:	<p>The Audio link will be available on the company website. Please access the link here - https://jubilantingrevia.com/investors/financials/quarterly-results</p>

For More Information



Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to global quality standards and has a broad portfolio of 130+ products.

It has over 45 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: www.jubilantingrevia.com

For Investors:

Pavleen Taneja

Jubilant Ingrevia Limited.

☎ Ph: +91 120 436 1000

✉ E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar, CDR India

☎ Ph: +91 22 6645 1209

✉ E-mail: siddharth@cdr-india.com

For Media:

Sandipan Ghatak

☎ Ph: +91 120 436 1062

✉ E-mail: sandipan.ghatak@jubl.com

Sahir Seth:

☎ Ph: +91 9999270119

✉ E-mail: sahir.seth@adfactorspr.com

Thank you for your time